Alnylam Pharmaceuticals logo
Alnylam Pharmaceuticals
ALNY | NASDAQ
Chart Builder DCF Calculator
$159.73
-$5.31 (-3.22%)
At close: Nov 16, 2026, 4:00 PM ET
$160.20
+$0.47 (+0.29%)
After-hours: Nov 16, 2026, 7:51 PM ET

Alnylam Pharmaceuticals Company Profile

Company profile explained

Company Profile

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.

Key Executives

Name Position
Yvonne L. Greenstreet Chief Executive Officer & Director
Bryan Andrew Supran Chief Legal Officer
Jeffrey V. Poulton Chief Financial Officer & Executive Vice President
Joshua Brodsky Vice President of Investor Relations
Kevin Joseph Fitzgerald Executive Vice President, Chief Scientific Officer and Head of Early Research & Early Development
Melissa McLaughlin Chief Human Resources Officer
Phillip A. Sharp Co-Founder, Member of the Scientific Advisory Board
Piyush Sharma Chief Ethics & Compliance Officer
Pushkal Garg Executive VP & Chief Research & Development Officer
Timothy J. Maines Chief Technical Operations & Quality Officer
Tolga Tanguler Executive VP & Chief Commercialization Officer

Latest SEC Filings

Date Type Title
Oct 30, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Oct 29, 2026 10-Q Quarterly Report
Oct 29, 2026 8-K Current Report
Oct 06, 2026 4 Filing
Sep 22, 2026 4 Filing
Jul 30, 2026 10-Q Quarterly Report
Jul 30, 2026 8-K Current Report
Jun 03, 2026 4 Filing
Jun 03, 2026 4 Filing
Jun 03, 2026 3 Filing
View All SEC Filings ➞
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals logo
Country United States
IPO Date Jun 1, 2004
Industry Biotechnology
Sector Healthcare
Employees 2,500
CEO Yvonne L. Greenstreet

Contact Details

675 West Kendall Street Cambridge, Massachusetts 02142 United States

Stock Details

Ticker Symbol ALNY
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001178670
CUSIP Number 02043Q107
ISIN Number US02043Q1076
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.